MOR208 Trials in R/R DLBCL Investigating the Fc-enhanced anti-CD19 antibody MOR208 in relapsed and/or refractory DLBCL NOW ENROLLING MOR208 is an investigational agent and has not been approved by regulatory agencies B-MIND A Phase II/III, Randomised, Multicentre Study of MOR208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diff use Large B-Cell Lymphoma (R/R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT) Cycle 1 - 6 Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) * Patients after failure of ASCT or not eligible for HDC and ASCT * 1-3 prior systemic regimens. At least one prior regimen included an anti-CD20 targeted agent * ECOG 0 to 2 Until PD MOR208 + Bendamustine MOR208 Rituximab + Bendamustine Rituximab R 1:1 N=330 For further information visit www.clinicaltrials.gov (NCT02763319) or contact medical@morphosys.com. L-MIND A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diff use Large B-Cell Lymphoma (R/R DLBCL) Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) * Patients after failure of ASCT or not eligible for HDC and ASCT * 1-3 prior systemic regimens. At least one prior regimen included an anti-CD20 targeted agent * ECOG 0 to 2 Cycle 1 - 12 Until PD, max. 24 cycles MOR208 + Lenalidomide MOR208 N=80 For more information visit www.clinicaltrials.gov (NCT02399085) or contact medical@morphosys.com. MorphoSys is dedicated to developing exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Together with its partners, MorphoSys has built a therapeutic pipeline of more than 100 programs in R&D, 10 thereof in clinical development for patients with solid tumors and hematological malignancies. www.morphosys.com © 2017 MorphoSys AG All rights reserved. October 2017